Trevor Squire, DO
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $97,643 of the $112,315 with a category attached, or 86.9%. 17 manufacturers reported payments, led by Lilly USA, LLC at 34.7% of the total. Among neurology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $652.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$39K
- Teva Pharmaceuticals USA, Inc.$24K
- SK Life Science, Inc.$24K
- Pfizer$14K
- Acadia Pharmaceuticals Inc$10K
- Livanova USA, Inc.$240
- plus $691 from 11 others
What the payments were for
- Consulting fees$8,3257%
- Speaking & faculty fees$97,64387%
- Grants$880%
- Travel & lodging$3,3603%
- Food & beverage$2,7382%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 56 | $38,918 |
| Teva Pharmaceuticals USA, Inc. | 23 | $24,167 |
| SK Life Science, Inc. | 43 | $23,873 |
| Pfizer | 9 | $14,197 |
| Acadia Pharmaceuticals Inc | 17 | $10,229 |
| Livanova USA, Inc. | 6 | $240 |
| Greenwich Biosciences, Inc. | 5 | $170 |
| Biogen | 1 | $150 |
| DIXI Medical USA Corp | 1 | $75 |
| Inspire Medical Systems, Inc. | 1 | $64 |
| UCB, Inc. | 2 | $58 |
| Novartis | 3 | $53 |
| Sanofi | 1 | $46 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Argenx US, Inc. | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMGALITY$22,525
- XCOPRI$18,786
- AUSTEDO$17,638
- NURTEC ODT$14,125
- KISUNLA$10,000
- NUPLAZID$9,803
- Austedo XR$4,957
- Cenobamate$4,173
- REYVOW$1,925
- TYSABRI$150
How this compares
$112,315 in reported general payments places this provider in the 90th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 40 | $326,946 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $98,706 |
| Emgality PenGalcanezumab-Gnlm | 109 | $76,965 |
| Aimovig AutoinjectorErenumab-Aooe | 49 | $50,269 |
| Austedo XrDeutetrabenazine | 24 | $46,165 |
| XcopriCenobamate | 24 | $41,117 |
| Trokendi XrTopiramate | 18 | $38,127 |
| BriviactBrivaracetam | 26 | $36,229 |
| EpidiolexCannabidiol (Cbd) | 13 | $31,494 |
| Nurtec OdtRimegepant Sulfate | 28 | $31,472 |
| AptiomEslicarbazepine Acetate | 13 | $24,870 |
| Lacosamide | 182 | $18,030 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 273 | $15,183 |
| VimpatLacosamide | 13 | $14,440 |
| Topiramate ErTopiramate | 20 | $11,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt, Relpax | $14,197 | $367,96279 claims |
| UCB, Inc.Briviact, Vimpat | $58 | $50,67039 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $24,167 | $46,16524 claims |
| SK Life Science, Inc.Xcopri | $23,873 | $41,11724 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $14 | $38,12718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 157 neurology providers in Utah.
Other neurology in Ogden
- Richard HammondOgden$707K
- Brett AlldredgeOgden$37K
- Timothy WestSalt Lake City$856K
- Jeffrey GrovesDraper$628K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Yashma PatelLehi$251K
- Albert SmithSalt Lake City$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.